All In Biotech

Drug Trial Radar · NCT07401199

Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)

A Prospective, Multicenter, Real-World Cohort Study for the Development and Validation of a Multimodal Artificial Intelligence System to Predict Response to Neoadjuvant Chemo-Immunotherapy in Locally Advanced Gastric Cancer (The PRISM-GC Study)

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Feb 5, 2026

Primary completion

Dec 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Qun ZhaoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shijiazhuang People's Hospital; Baoding Central Hospital; Hengshui People's Hospital; Wuhan University Affiliated People's Hospital; The Fifth Affiliated Hospital of Anhui Medical University
First posted
Feb 10, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gastric cancer is a major global health challenge. Currently, a combination of chemotherapy and immunotherapy (PD-1 inhibitors) is frequently used before surgery to shrink tumors, a strategy known as neoadjuvant therapy. While this approach is effective for many patients, responses vary significantly, and there are currently no reliable tools to predict which patients will benefit the most before treatment begins. The PRISM-GC study aims to develop and validate a novel Artificial Intelligence (AI) system to address this need. This is a prospective, observational study that will collect data from patients diagnosed with locally advanced gastric cancer who are scheduled to receive standard neoadjuvant chemotherapy combined with immunotherapy in a real-world clinical setting. The specific choice of immunotherapy drug is determined by the treating physician and is not dictated by the study. Researchers will analyze standard preoperative CT scans and pathological tissue slides using advanced deep learning algorithms. The goal is to create a "multimodal" AI model that can accurately predict how well a tumor will respond to treatment (specifically, whether the tumor will disappear or shrink significantly). If successful, this AI tool could help doctors personalize treatment plans in the future, ensuring that each patient receives the most effective therapy while avoiding unnecessary side effects.

Conditions

  • Gastric Cancer (GC)
  • Locally Advanced Gastric Cancer

Interventions

  • Standard of Care PD-1 InhibitorsDrug

    Patients receive standard neoadjuvant chemotherapy (e.g., SOX or XELOX regimen) combined with any NMPA-approved PD-1 inhibitor (including but not limited to Sintilimab, Tislelizumab, Camrelizumab, etc.) as determined by the treating physician in real-world practice.

  • Multimodal AI AssessmentDiagnostic test

    Non-invasive assessment using a multimodal deep learning system (DeepComp) to analyze preoperative contrast-enhanced CT images and pathological slides. The AI model predicts the probability of pathological complete response (pCR) but does not alter the clinical treatment plan.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Predictive Accuracy of the Multimodal AI Model for Pathological Complete Response (pCR)Time frame: From baseline assessment to postoperative pathological evaluation (approximately 5 months)
  2. Pathological Complete Response (pCR) RateTime frame: At the time of postoperative pathological evaluation (approximately 1 month after surgery)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • The Fifth Affiliated Hospital of Anhui Medical University

    Fuyang, Anhui, China · Recruiting

  • Cangzhou People's Hospital

    Cangzhou, Hebei, China · Recruiting

  • Hengshui People's Hospital

    Hengshui, Hebei, China · Recruiting

  • The Second Affiliated Hospital of Xingtai Medical College

    Xingtai, Hebei, China · Recruiting

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • Yichang Central Hospital

    Yichang, Hubei, China · Recruiting

  • Baoding Central Hospital

    Baoding, None Selected, China · Recruiting

  • Shijiazhuang People's Hospital

    Shijiazhuang, None Selected, China · Recruiting

  • the Fourth Hospital of Hebei Medical University

    Shijiazhuang, None Selected, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.